N@N

MEAS, NXTM, GGC, OSUR, NEWS, ALXA Expected To Be Lower After Earnings Releases on Wednesday

^{Published on 2009-07-30 09:33:27, Last Modified on 2010-12-22 14:38:55 - WOPRAI}
 

July 30, 2009 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Wednesday, August 5th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and August earnings reports. Measurement Specialties (NASDAQ: MEAS), NxStage Medical (NASDAQ: NXTM), Georgia Guld (NYSE: GGC), OraSure Technologies (NASDAQ: OSUR), NewStar Financial (NASDAQ: NEWS) and Alexza Pharmaceuticals (NASDAQ: ALXA) are all expected to be lower after their earnings are released Wednesday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go lower after earnings are released Wednesday:

Symbol Company # of Reports Quarter Release Time

MEAS Measurement Specialties 12 quarters Q1 After

NXTM NxStage Medical, Inc. 12 quarters Q2 Before

GGC Georgia Gulf 12 quarters Q2 After

OSUR OraSure Technologies August earnings Q2 After

NEWS NewStar Financial, Inc. 12 quarters Q2 Before

ALXA Alexza Pharmaceuticals 12 quarters Q2 After

Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event because the information is so vital to the market's perception of the vitality of that company.

This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists.

Measurement Specialties, Inc. (NASDAQ: MEAS) engages in the design, development, and manufacture of sensors and sensor-based systems for original equipment manufacturers and end users. It offers pressure sensors and transducers, linear/rotary position sensors, piezoelectric polymer film sensors, custom microstructures, load cells, accelerometers, optical sensors, humidity, and temperature sensors. The company's technologies include piezo-resistive silicon sensors, application-specific integrated circuits, micro-electromechanical systems, piezoelectric polymers, foil strain gauges, force balance systems, fluid capacitive devices, linear and rotational variable differential transformers, electromagnetic displacement sensors, hygroscopic capacitive sensors, ultrasonic sensors, optical sensors, negative thermal coefficient ceramic sensors, and mechanical resonators. Its products are used for automotive, medical, consumer, military/aerospace, and industrial applications. The company sells its sensor products through regional sales managers, distributors, and outside sales representatives in the United States, France, Germany, Ireland, Switzerland, and China. Measurement Specialties, Inc. was founded in 1981 and is headquartered in Hampton, Virginia.

NxStage Medical, Inc. (NASDAQ: NXTM), a medical device company, engages in the development, manufacture, and marketing of products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures in the United States. The companya�s primary product includes NxStage System One, a portable hemodialysis system, which is designed to provide hemodialysis therapy. It also sells needles, blood tubing, and other extracorporeal products to dialysis centers for the treatment of end-stage renal disease. NxStage Medical, Inc. offers its products primarily to dialysis clinics, as well as other hospitals that treat acute kidney failure and fluid overload. The company, formerly known as QB Medical, Inc., was founded in 1998 and is headquartered in Lawrence, Massachusetts.

Georgia Gulf Corporation (NSYE: GGC) engages in manufacturing and marketing chlorovinyls and aromatics chemicals, and vinyl-based building and home improvement products in the United States and internationally. The company operates in four segments, Chlorovinyls; Window and Door Profiles and Mouldings Products; Outdoor Building Products; and Aromatics. The chlorovinyls segment offers chlorine, caustic soda, ethylene dichloride, and vinyl resins and compounds. The Window and Door Profiles and Mouldings Products segment provides vinyl window profiles, including frames, sashes, trim, and other components, as well as vinyl patio door components and fabricated patio doors to window and door fabricators. This segment also manufactures and markets extruded decorative mouldings and millwork. The Outdoor Building Products segment provides siding products, including vinyl siding, and various accessories, such as vinyl soffit, aluminum soffit, fascia trim and molded vent mounts, and exterior shutters; pipe and pipe fittings for the municipal and electrical markets, as well as for plumbing applications; and deck, fence and rail, and fabricated aluminum products. The Aromatics segment offers cumene, and the co-products, phenol acetone and alpha methyl styrene. It markets its vinyl-based building and home improvement products under the Royal Group brands. The company was founded in 1984 and is based in Atlanta, Georgia.

OraSure Technologies, Inc. (NASDAQ: OSUR) develops, manufactures, and markets oral fluid diagnostic products and specimen collection devices. The companya�s products include OraQuick ADVANCE HIV-1/2, a point-of-care test for antibodies to the human immunodeficiency virus (HIV) type 1 and type 2; OraQuick HIV-1/2 OTC, a point-of-care oral fluid HIV-1/2 test; OraQuick HCV, a point-of-care test for antibodies to the hepatitis C virus; OraSure, an oral fluid collection device for the detection of antibodies to HIV-1; and Intercept, an oral fluid collection device used for oral fluid drugs of abuse testing. It also offers MICRO-PLATE DOA Assays for the detection of drugs in an oral fluid sample; cryosurgical systemsa"professional for the removal of warts and benign skin lesions; and cryosurgical systemsa"OTC for the removal of common and plantar warts. In addition, OraSure Technologies provides immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test; and Q.E.D., a point-of-care saliva alcohol test. It develops Homogeneous DOA Assays; cryosurgical systemsa"OTC for an indication other than common warts or plantar warts; and OraQuick, a point-of-care testing platform. Further, the company provides various diagnostic products, including immunoassays and in vitro diagnostic tests that are used on other specimen types, and medical devices. OraSure Technologies sells its products through direct sales, strategic partnerships, and independent distributors to clinical laboratories, hospitals, clinics, community-based organizations and public health organizations, distributors, government agencies, physiciansa� offices, and commercial and industrial entities in the United States, Europe, and internationally. It has collaboration agreements with Roche Diagnostics and Schering-Plough Corporation. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.

NewStar Financial, Inc. (NASDAQ: NEWS), a commercial finance company, provides customized debt financing solutions. The company principally focuses on the direct origination of loans and other debt products. The company provides senior secured and senior subordinated debt products, including revolving warehouse facilities, amortizing loans, term loans, and debt securities; second lien; mezzanine and subordinated debt; and equity and equity-linked products primarily to healthcare, manufacturing and industrial, financial services, energy/chemical services, printing/publishing, consumer, retail and restaurants, and business services industries. It also offers commercial real estate loans and other debt products primarily through property investors, specialized commercial real estate brokers, regional banks, and other financial intermediaries. The company is headquartered in Boston, Massachusetts.

Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA), a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches. Its products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the companya�s single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. The company was founded in 2000 and is based in Mountain View, California.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

One example from the SqueezeTrigger database is approximately 2.6 billion short sale transactions going back to January 1, 2005, and SqueezeTrigger calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

Go to www.SqueezeTrigger.com to find out the exact price that the entire Total Short Interest will start covering!

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641